Trials of cannabis for Parkinson's motor symptoms (tremor, rigidity) have largely disappointed: the National Academies grade evidence as insufficient, and levodopa remains untouchable as the treatment core. What patients consistently report — and small studies partially support — is help with the non-motor burden: sleep fragmentation, pain, anxiety, and appetite.
Two Parkinson's-specific cautions: orthostatic dizziness (already common in PD and worsened by THC) raises fall risk, so dosing starts at the very bottom; and cognitive effects deserve monitoring in a population where cognition is already under pressure. Coordinate with your movement-disorder neurologist — cannabis layers onto PD care; it doesn't modify the disease.
The information on this site is for educational purposes only and is not medical or legal advice. Cannabis use carries risks; consult a licensed physician about whether medical cannabis is appropriate for you. Federal status (as of June 2026): marijuana dispensed under state medical licenses and FDA-approved cannabis products are Schedule III controlled substances; all other marijuana remains Schedule I under U.S. federal law.